Literature DB >> 20039422

Good and bad memories following rituximab therapy.

E William St Clair.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20039422      PMCID： PMC2806494          DOI： 10.1002/art.25039

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  27 in total

1.  Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab).

Authors:  G V Gonzalez-Stawinski; P B Yu; S D Love; W Parker; R D Davis
Journal:  Clin Immunol       Date:  2001-02       Impact factor: 3.969

2.  Anti-pneumococcal antibody response in normal subjects: a meta-analysis.

Authors:  E S Go; Z K Ballas
Journal:  J Allergy Clin Immunol       Date:  1996-07       Impact factor: 10.793

3.  Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.

Authors:  M C Kapetanovic; T Saxne; A Sjöholm; L Truedsson; G Jönsson; P Geborek
Journal:  Rheumatology (Oxford)       Date:  2005-11-15       Impact factor: 7.580

4.  Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174.

Authors:  Christopher M Bearden; Avinash Agarwal; Benita K Book; Carlos A Vieira; Richard A Sidner; Hans D Ochs; Marquerite Young; Mark D Pescovitz
Journal:  Am J Transplant       Date:  2005-01       Impact factor: 8.086

5.  B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae.

Authors:  Karen M Haas; Jonathan C Poe; Douglas A Steeber; Thomas F Tedder
Journal:  Immunity       Date:  2005-07       Impact factor: 31.745

Review 6.  Human IgM+CD27+ B cells: memory B cells or "memory" B cells?

Authors:  Stuart G Tangye; Kim L Good
Journal:  J Immunol       Date:  2007-07-01       Impact factor: 5.422

7.  Rituximab treatment results in impaired secondary humoral immune responsiveness.

Authors:  Lizet E van der Kolk; Joke W Baars; Martin H Prins; Marinus H J van Oers
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

Review 8.  Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines.

Authors:  R J Cox; K A Brokstad; P Ogra
Journal:  Scand J Immunol       Date:  2004-01       Impact factor: 3.487

9.  Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus.

Authors:  Jörn E Schmitz; Marcelo J Kuroda; Sampa Santra; Meredith A Simon; Michelle A Lifton; Wenyu Lin; Rajinder Khunkhun; Michael Piatak; Jeffrey D Lifson; Gudrun Grosschupff; Rebecca S Gelman; Paul Racz; Klara Tenner-Racz; Keith A Mansfield; Norman L Letvin; David C Montefiori; Keith A Reimann
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

10.  Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.

Authors:  Sander van Assen; Albert Holvast; Cornelis A Benne; Marcel D Posthumus; Miek A van Leeuwen; Alexandre E Voskuyl; Marlies Blom; Anke P Risselada; Aalzen de Haan; Johanna Westra; Cees G M Kallenberg; Marc Bijl
Journal:  Arthritis Rheum       Date:  2010-01
View more
  12 in total

1.  Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.

Authors:  John H Baird; David J Epstein; John S Tamaresis; Zachary Ehlinger; Jay Y Spiegel; Juliana Craig; Gursharan K Claire; Matthew J Frank; Lori Muffly; Parveen Shiraz; Everett Meyer; Sally Arai; Janice Wes Brown; Laura Johnston; Robert Lowsky; Robert S Negrin; Andrew R Rezvani; Wen-Kai Weng; Theresa Latchford; Bita Sahaf; Crystal L Mackall; David B Miklos; Surbhi Sidana
Journal:  Blood Adv       Date:  2021-01-12

2.  Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis.

Authors:  Meliha C Kapetanovic; Lars-Erik Kristensen; Tore Saxne; Teodora Aktas; Andreas Mörner; Pierre Geborek
Journal:  Arthritis Res Ther       Date:  2014-01-02       Impact factor: 5.156

Review 3.  Rituximab for people with multiple sclerosis.

Authors:  Graziella Filippini; Jera Kruja; Cinzia Del Giovane
Journal:  Cochrane Database Syst Rev       Date:  2021-11-08

Review 4.  A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.

Authors:  Maryam Noori; Shadi Azizi; Farhan Abbasi Varaki; Seyed Aria Nejadghaderi; Davood Bashash
Journal:  Int Immunopharmacol       Date:  2022-07-12       Impact factor: 5.714

Review 5.  B-cell Therapy for Multiple Sclerosis: Entering an era.

Authors:  Ariele L Greenfield; Stephen L Hauser
Journal:  Ann Neurol       Date:  2018-01       Impact factor: 10.422

6.  Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab.

Authors:  Marion Heusele; Pierre Clerson; Benoit Guery; Marc Lambert; David Launay; Guillaume Lefevre; Sandrine Morell-Dubois; Hélène Maillard; Noémie Le Gouellec; Pierre-Yves Hatron; Eric Hachulla
Journal:  Clin Rheumatol       Date:  2014-02-02       Impact factor: 2.980

7.  Model-Informed Dosing of Venetoclax in Healthy Subjects: An Exposure-Response Analysis.

Authors:  Nimita Dave; Sathej Gopalakrishnan; Sven Mensing; Ahmed Hamed Salem
Journal:  Clin Transl Sci       Date:  2019-08-07       Impact factor: 4.689

8.  Increased antibody response after SARS-CoV-2 mRNA-based vaccination in rituximab-treated patients with previous COVID-19 infection.

Authors:  Jérôme Avouac; Roba Ghossan; Omar Al Tabaa; Alice Combier; Alexia Steelandt; Marion Thomas; Olivier Fogel; Alice Andrée Mariaggi; Jean-François Meritet; Flore Rozenberg; Anna Molto; Corinne Miceli-Richard; Yannick Allanore
Journal:  Rheumatology (Oxford)       Date:  2022-06-28       Impact factor: 7.046

9.  Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis.

Authors:  Meliha Crnkic Kapetanovic; Tore Saxne; Göran Jönsson; Lennart Truedsson; Pierre Geborek
Journal:  Arthritis Res Ther       Date:  2013-10-30       Impact factor: 5.156

10.  Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients.

Authors:  Abi Vijenthira; Inna Gong; Stephen D Betschel; Matthew Cheung; Lisa K Hicks
Journal:  Blood Adv       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.